Federal Circuit Review | June 2026
When ‘Any Patent’ Means No Patent: Federal Circuit Reverses Non-Specific Verdict In Ollnova Technologies Ltd. v. Ecobee Technologies ULC [Opinion], Appeal No. 25-1045, the Federal Circuit held that a...
Carol Pitzel Cruz Comments in Law360 on Enablement Analysis in Pharmaceutical Patent Litigation
Knobbe Martens partner Carol Pitzel Cruz was quoted in a recent Law360 article on the Federal Circuit’s decision in Wyeth v. AstraZeneca, a patent infringement dispute centered on Section 112...
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient With “A Unit Dosage” in Wyeth LLC v. Astrazeneca Pharmaceuticals LP.
Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal growth factor receptor...
Subscribe for News and Updates